The p53 isoform, Δ133p53, stimulates angiogenesis and tumour progression

Oncogene

Volumn 32, Issue 17, 2013, Pages 2150-2160

  Bernard, H ^a,b   Garmy Susini, B ^a,c   Ainaoui, N ^a   Van Den Berghe, L ^a,c   Peurichard, A ^a   Javerzat, S ^c,d   Bikfalvi, A ^c,d   Lane, D P ^b   Bourdon, J C ^b   Prats, A C ^a  

^a UNIVERSITÉ DE TOULOUSE   (France)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

^c INSERM   (France)

^d UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

angiogenesis; cancer; glioblastoma; isoform; p53

Indexed keywords

PROTEIN P53; SMALL INTERFERING RNA;

ANGIOGENESIS; APOPTOSIS; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CELL CYCLE ARREST; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIUM CELL; GENE EXPRESSION; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; OSTEOSARCOMA CELL; PRIORITY JOURNAL;

ANGIOGENIC PROTEINS; ANIMALS; BRAIN NEOPLASMS; CATTLE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CHICK EMBRYO; CHORIOALLANTOIC MEMBRANE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN ISOFORMS; TUMOR BURDEN; TUMOR SUPPRESSOR PROTEIN P53;

MUS;

EID: 84876944251     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.242     Document Type: Article

References (30)

1. Bourdon JC. p53 and its isoforms in cancer. Br J Cancer 2007; 97: 277-282.
2. Bourdon JC, Fernandes K, Murray-Zmijewski F, Liu G, Diot A, Xirodimas DP et al. p53 isoforms can regulate p53 transcriptional activity. Genes Dev 2005; 19: 2122-2137. (Pubitemid 41330315)
3. Chen J, Ng SM, Chang C, Zhang Z, Bourdon JC, Lane DP et al. p53 isoform delta113p53 is a p53 target gene that antagonizes p53 apoptotic activity via BclxL activation in zebrafish. Genes Dev 2009; 23: 278-290.
4. Aoubala M, Murray-Zmijewski F, Khoury MP, Fernandes K, Perrier S, Bernard H et al. p53 directly transactivates Delta133p53alpha, regulating cell fate outcome in response to DNA damage. Cell Death Differ 2011; 18: 248-258.
5. Fujita K, Mondal AM, Horikawa I, Nguyen GH, Kumamoto K, Sohn JJ et al. p53 isoforms Delta133p53 and p53beta are endogenous regulators of replicative cellular senescence. Nat Cell Biol 2009; 11: 1135-1142.
6. Teodoro JG, Evans SK, Green MR. Inhibition of tumor angiogenesis by p53: a new role for the guardian of the genome. J Mol Med 2007; 85: 1175-1186. (Pubitemid 47622219)
7. Fraisl P, Mazzone M, Schmidt T, Carmeliet P. Regulation of angiogenesis by oxygen and metabolism. Dev Cell 2009; 16: 167-179.
8. Pouyssegur J, Dayan F, Mazure NM. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 2006; 441: 437-443. (Pubitemid 44050138)
9. Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994; 265: 1582-1584. (Pubitemid 24308973)
10. Folkman J. Tumor suppression by p53 is mediated in part by the antiangiogenic activity of endostatin and tumstatin. Sci STKE 2006; 2006: pe35.
11. Galy B, Creancier L, Zanibellato C, Prats AC, Prats H. Tumour suppressor p53 inhibits human fibroblast growth factor 2 expression by a post-transcriptional mechanism. Oncogene 2001; 20: 1669-1677. (Pubitemid 32368014)
12. Pal S, Datta K, Mukhopadhyay D. Central role of p53 on regulation of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in mammary carcinoma. Cancer Res 2001; 61: 6952-6957. (Pubitemid 32896524)
13. Ravi R, Mookerjee B, Bhujwalla ZM, Sutter CH, Artemov D, Zeng Q et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev 2000; 14: 34-44. (Pubitemid 30051577)
14. Ueba T, Nosaka T, Takahashi JA, Shibata F, Florkiewicz RZ, Vogelstein B et al. Transcriptional regulation of basic fibroblast growth factor gene by p53 in human glioblastoma and hepatocellular carcinoma cells. Proc Natl Acad Sci USA 1994; 91: 9009-9013.
15. Giuriato S, Ryeom S, Fan AC, Bachireddy P, Lynch RC, Rioth MJ et al. Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch. Proc Natl Acad Sci USA 2006; 103: 16266-16271. (Pubitemid 44715185)
16. Naumov GN, Akslen LA, Folkman J. Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch. Cell Cycle 2006; 5: 1779-1787. (Pubitemid 44435320)
17. Wong ML, Prawira A, Kaye AH, Hovens CM. Tumour angiogenesis: its mechanism and therapeutic implications in malignant gliomas. J Clin Neurosci 2009; 16: 1119-1130.
18. Marcel V, Vijayakumar V, Fernandez-Cuesta L, Hafsi H, Sagne C, Hautefeuille A et al. p53 regulates the transcription of its Delta133p53 isoform through specific response elements contained within the TP53 P2 internal promoter. Oncogene 2010; 29: 2691-2700.
19. Hagedorn M, Javerzat S, Gilges D, Meyre A, de Lafarge B, Eichmann A et al. Accessing key steps of human tumor progression in vivo by using an avian embryo model. Proc Natl Acad Sci USA 2005; 102: 1643-1648. (Pubitemid 40209221)
20. Khoury MP, Bourdon JC. p53 Isoforms: an intracellular microprocessor Genes Cancer 2011; 2: 453-465.
21. Bourdon JC, Khoury MP, Diot A, Baker L, Fernandes K, Aoubala M et al. p53 mutant breast cancer patients expressing p53gamma have as good a prognosis as wild-type p53 breast cancer patients. Breast Cancer Res 2011; 13: R7.
22. Davidson WR, Kari C, Ren Q, Daroczi B, Dicker AP, Rodeck U. Differential regulation of p53 function by the N-terminal DeltaNp53 and Delta113p53 isoforms in zebrafish embryos. BMC Dev Biol 2010; 10: 102.
23. Nakagawa T, Takahashi M, Ozaki T, Watanabe Ki K, Todo S, Mizuguchi H et al. Autoinhibitory regulation of p73 by Delta Np73 to modulate cell survival and death through a p73-specific target element within the Delta Np73 promoter. Mol Cell Biol 2002; 22: 2575-2585. (Pubitemid 34262980)
24. Ohgaki H, Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am J Pathol 2007; 170: 1445-1453. (Pubitemid 47339290)
25. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009; 15: 232-239.
26. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15: 220-231.
27. Sirven A, Ravet E, Charneau P, Zennou V, Coulombel L, Guetard D et al. Enhanced transgene expression in cord blood CD34(\+)-derived hematopoietic cells, including developing T cells and NOD/SCID mouse repopulating cells, following transduction with modified trip lentiviral vectors. Mol Ther 2001; 3: 438-448. (Pubitemid 32509837)
28. Bossard C, Van den Berghe L, Laurell H, Castano C, Cerutti M, Prats AC et al. Antiangiogenic properties of fibstatin, an extracellular FGF-2-binding polypeptide. Cancer Res 2004; 64: 7507-7512. (Pubitemid 39372095)
29. Jensen MM, Jorgensen JT, Binderup T, Kjaer A. Tumor volume in subcutaneous mouse xenografts measured by microCT is more accurate and reproducible than determined by 18F-FDG-microPET or external caliper. BMC Med Imag 2008; 8: 16.
30. Saidi A, Javerzat S, Bellahcene A, De Vos J, Bello L, Castronovo V et al. Experimental anti-Angiogenesis causes upregulation of genes associated with poor survival in glioblastoma. Int J Cancer 2008; 122: 2187-2198. (Pubitemid 351542321)